Clinical

Exposure to tobacco smoke as a fetus or during early childhood can cause genetic changes that can increase a child’s risk of developing acute lymphoblastic leukemia (ALL).

Clinical pathways can successfully be used to drive physicians to choose a less costly regimen when the efficacy and toxicity of different treatment regimens for metastatic colorectal cancer are comparable, according to a study in the Journal of Oncology Practice.

A study presented at the annual meeting of the American Association for Cancer Research predicts a shift in the number and the pattern of cancer incidence among those infected with the human immunodeficiency virus (HIV).

Patients with chorea associated with Huntington’s disease have the first new treatment in nearly a decade. The FDA has approved Teva Pharmaceutical Industries Ltd’s Austedo (deutetrabenazine) for the treatment of chorea, which affects nearly 90% of patients with Huntington's.

The patient voice is becoming more important as healthcare moves to a value-based, patient-centered system of care, but just amplifying the patient voice is not enough. There needs to not only be amplification, but also a constructive response from the health system, said Thomas Lee, MD, chief medical officer at Press Ganey, during his presentation at the National Quality Forum Annual Conference.

The 5-year survival estimate from a study evaluating nivolumab in a subset of patients with advanced non-small cell lung cancer (NSCLC) is significantly longer following treatment discontinuation.

Behind the scenes there are a number of advances that Patricia Flatley Brennan, RN, PhD, director of the National Library of Medicine, would like to see take place to make it easier to get literature into people's hands.

The full approval comes in less than 2 years of the drug's accelerated approval by the FDA.

Being blind, intellectually disabled, or having a spinal cord injury can reduce the probability of a person being screened for colorectal cancer.

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused clinical review on the topic of the PCSK9 inhibitor Repatha (evolocumab), and its impact on low-density lipoprotein cholesterol (LDL-C).

A study published in the journal Cancer has found that the rate of advanced imaging at the time of breast cancer diagnosis reduced during the period between 2008 and 2015 in the state of Michigan.

The Academy of Managed Care Pharmacy Annual Meeting kicked off on March 28, 2017, in Denver, Colorado, with a look at the specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

Results from the randomized NOVA trial convinced the FDA to approve niraparib (Zejula) as maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who are sensitive to platinum-based chemotherapy.

According to research conducted at the Colorado School of Public Health at CU Anschutz, nearly 75% of smokers have low socioeconomic status.

While the orphan drug market has been growing, a new study argues that the current unmet needs of patients with rare disease proves that current incentives are not efficiently stimulating orphan drug development.

At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.

On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.